Cargando…
Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand
BACKGROUND: Public payer reimbursement for non-oncology drugs in Canada, including orphan drugs, is based on recommendations by the Common Drug Review (CDR) (with the exception of Quebec). CDR has been criticized for negative recommendations for orphan drugs and contributing to delays in patient acc...
Autores principales: | McCormick, John I., Berescu, L. Diana, Tadros, Nabil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791218/ https://www.ncbi.nlm.nih.gov/pubmed/29382371 http://dx.doi.org/10.1186/s13023-018-0759-9 |
Ejemplares similares
-
Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia
por: Zhou, Na, et al.
Publicado: (2022) -
Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019) -
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016) -
Dual Attention and Patient Similarity Network for drug recommendation
por: Wu, Jialun, et al.
Publicado: (2023) -
Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
por: Morrell, Liz, et al.
Publicado: (2017)